Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

被引：20

作者：

Morgan, Gareth ^{[1
]}

Palumbo, Antonio ^{[2
]}

Dhanasiri, Sujith ^{[3
]}

Lee, Dawn ^{[4
]}

Weisel, Katja ^{[5
]}

Facon, Thierry ^{[6
]}

Delforge, Michel ^{[7
]}

Oriol, Albert ^{[8
]}

Zaki, Mohamed ^{[9
]}

Yu, Xin ^{[9
]}

Sternas, Lars ^{[9
]}

Jacques, Christian ^{[9
]}

Akehurst, Ron ^{[4
,10
]}

Offner, Fritz ^{[11
]}

Dimopoulos, Meletios A. ^{[12
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[2] Via Univ Torino, Turin, Italy

[3] Celgene Ltd, London, England

[4] Bres Med, Sheffield, S Yorkshire, England

[5] Univ Tubingen, Tubingen, Germany

[6] CHU Lille, Serv Malad Sang, F-59037 Lille, France

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Celgene Corp, Summit, NJ USA

[10] Univ Sheffield, Sheffield, S Yorkshire, England

[11] Univ Ziekenhuis Gent, Ghent, Belgium

[12] Univ Athens, Alexandra Hosp, Sch Med, Athens 11528, Greece

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 168卷 / 06期

关键词：

multiple myeloma; pomalidomide; survival; crossover; bias;

D O I：

10.1111/bjh.13227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 70months (127 vs. 57months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

引用

页码：820 / 823

页数：4

共 50 条

[1] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: ADJUSTING FOR CROSSOVER IN THE MM-003 TRIAL FOR POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE
Morgan, G.
San Miguel, J. F.
Dhanasiri, S.
Lee, D.
Palumbo, A.
Facon, T.
Zaki, M.
Yu, X.
Sternas, L.
Jacques, C.
Weisel, K.
Offner, F.
Dimopoulos, M.
[J]. HAEMATOLOGICA, 2014, 99 : 365 - 366
[2] IMPACT OF STABLE DISEASE AS A RESPONSE TO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE ON SURVIVAL OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE MM-003 TRIAL
Moreau, P.
Weisel, K.
Song, K.
Gibson, C.
Saunders, O.
Sternas, L.
Hong, K.
Zaki, K.
Dimopoulos, M. A.
[J]. HAEMATOLOGICA, 2015, 100 : 312 - 312
[3] Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
Moreau, Philippe
Weisel, Katja C.
Song, Kevin W.
Gibson, Craig J.
Saunders, Owain
Sternas, Lars Axel
Hong, Kevin
Zaki, Mohamed H.
Dimopoulos, Meletios A.
[J]. LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2839 - 2847
[4] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
Weisel, Katja
Moreau, Philippe
Gibson, Craig J.
Song, Kevin W.
Saunders, Owain
Sternas, Lars Axel
Hong, Kevin
Zaki, Mohamed H.
Dimopoulos, Meletios A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover.
Morgan, Gareth J.
San Miguel, Jesus
Dhanasiri, Sujith
Lee, Dawn
Palumbo, Antonio
Facon, Thierry
Zaki, Mohamed H.
Yu, Xin
Sternas, Lars Axel
Jacques, Christian
Weisel, Katja C.
Offner, Fritz
Dimopoulos, Meletios A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M. A.
Weisel, K.
Song, K. W.
Delforge, M.
Karlin, L.
Goldschmidt, H.
Moreau, P.
Banos, A.
Oriol, A.
Garderet, L.
Cavo, M.
Ivanova, V.
Alegre, A.
Martinez-Lopez, J.
Chen, C. I.
Spencer, A.
Knop, S.
Bahlis, N. J.
Renner, C.
Yu, X.
Hong, K.
Sternas, L.
Jacques, C.
Zaki, M. H.
San Miguel, J. F.
[J]. HAEMATOLOGICA, 2014, 99 : 365 - 365
[7] IMPACT OF ECOG PERFORMANCE STATUS ON OVERALL SURVIVAL AND HRQOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE MM-003 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (DEX) vs HIGH-DOSE DEX
Weisel, K.
San Miguel, J.
Song, K.
Delforge, M.
Lewis, P.
Yu, X.
Zaki, M.
Sternas, L.
Dimopoulos, M.
[J]. HAEMATOLOGICA, 2014, 99 : 518 - 518
[8] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Palumbo, Antonio
Belch, Andrew
Schey, Stephen
Sonneveld, Pieter
Sternas, Lars
Yu, Xin
Amatya, Ramesh
Monzini, Mara S.
Zaki, Mohamed
Jacques, Christian
Miguel, Jesus San
[J]. HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
[9] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[10] Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Weisel, Katja C.
Dimopoulos, Meletios A.
Moreau, Philippe
Lacy, Martha Q.
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Oriol, Albert
Alegre, Adrian
Chen, Christine
Cavo, Michele
Garderet, Laurent
Ivanova, Valentina
Martinez-Lopez, Joaquin
Knop, Stefan
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Miguel, Jesus San
[J]. HAEMATOLOGICA, 2016, 101 (07) : 872 - 878

← 1 2 3 4 5 →